Macular Degeneration Association

Therapeutic Areas: Oncology | Hematology

Hematologic Neoplasms Clinical Trials

A listing of Hematologic Neoplasms medical research trials actively recruiting patient volunteers. Use the filters below to narrow your search results.

 

Arizona

UPDATED

Scottsdale Arizona 85259-5499

A clinical trial seeking patients for a research study for the treatment of Haematological Malignancy, Multile Pyeolma (SAR650984)

UPDATED

Scottsdale Arizona 85259-5499

A clinical trial to evaluate treatments using SAR650984, pomalidomide and dexamethasone for patients with Haematological Malignancy

UPDATED

Scottsdale Arizona 85259

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

UPDATED

Scottsdale Arizona 85258

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

Scottsdale Arizona 85258

A Phase 1 clinical study for patients with Hematologic Neoplasms

California

UPDATED

Duarte California 91010-301

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Stanford California 94305

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Los Angeles California 90027

A clinical trial to evaluate treatments using BPX-501 T cells and AP1903 for patients

Colorado

UPDATED

Aurora Colorado 80045

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Florida

UPDATED

Miami Florida 33136

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Sarasota Florida 34232

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Tampa Florida 33612

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Illinois

UPDATED

Chicago Illinois 60611-3008

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Chicago Illinois 60637

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

Maryland

UPDATED

Baltimore Maryland 21287

A Phase 1 clinical study for patients with Hematologic Neoplasms

Massachusetts

UPDATED

Boston Massachusetts 02115

A clinical trial to evaluate treatments using SAR650984, pomalidomide and dexamethasone for patients with Haematological Malignancy

UPDATED

Boston Massachusetts 02114

A clinical trial to evaluate treatments using SAR650984, pomalidomide and dexamethasone for patients with Haematological Malignancy

UPDATED

Boston Massachusetts 02215

A Phase 1 clinical study for patients with Hematologic Neoplasms

UPDATED

Boston Massachusetts 02117

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Boston Massachusetts 02215

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Michigan

Ann Arbor Michigan 48109

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

Missouri

UPDATED

St. Louis Missouri 63110

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

New York

UPDATED

New York New York 10021

A Phase 1 clinical study for patients with Hematologic Neoplasms

UPDATED

New York New York 10065

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

New York New York 10065

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

New York New York

A clinical research study of Ibrutinib and Nivolumab for the treatment of Hematologic Neoplasms, Hematologic Malignancies

North Carolina

UPDATED

Charlotte North Carolina 28204

A clinical trial to evaluate treatments using SAR650984, pomalidomide and dexamethasone for patients with Haematological Malignancy

Ohio

UPDATED

Cleveland Ohio 44195

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Gahanna Ohio 43230

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Oregon

UPDATED

Portland Oregon 97239

A Phase 1 clinical study for patients with Hematologic Neoplasms

South Carolina

UPDATED

Greenville South Carolina 29605

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

Tennessee

UPDATED

Nashville Tennessee 37232

A clinical trial seeking patients for a research study for the treatment of Haematological Malignancy, Multile Pyeolma (SAR650984)

UPDATED

Nashville Tennessee 37203

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Nashville Tennessee 37232

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

Texas

UPDATED

Dallas Texas 75390-85520

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Houston Texas 77030

A Phase 1 clinical study for patients with Hematologic Neoplasms

UPDATED

Houston Texas 77030

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Houston Texas 77030

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

Dallas Texas 75390

A clinical trial to evaluate treatments using BPX-501 T cells and AP1903 for patients

Houston Texas 77030

A clinical trial to evaluate treatments using BPX-501 T cells and AP1903 for patients

San Antonio Texas 78229

A Phase 1 clinical study for patients with Hematologic Neoplasms

Utah

UPDATED

Salt Lake City Utah 84112-5550

A clinical trial seeking patients for a research study for the treatment of Haematological Malignancy, Multile Pyeolma (SAR650984)

Virginia

Fairfax Virginia 22031

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

Washington

UPDATED

Seattle Washington 98109

A Phase 1 clinical study for patients with Hematologic Neoplasms

France

UPDATED

Bordeaux 33076

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Pessac 33604

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

UPDATED

Villejuif 94805

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Italy

UPDATED

Roma 00161

A clinical research study of SAR650984, Bortezomib, Cyclophosphamide and Dexamethasone for the treatment of Haematological Malignancy, Newly diagnosed Multiple Myeloma (MM)

Spain

UPDATED

Pamplona 31008

A clinical research study of SAR650984, Bortezomib, Cyclophosphamide and Dexamethasone for the treatment of Haematological Malignancy, Newly diagnosed Multiple Myeloma (MM)

France

Lille

Patients are needed to participate in a clinical research study of OTX015 to evaluate Acute Leukemia or Other Hematological Malignacies